Klotho Neurosciences

What Klotho Neurosciences does

Klotho Neurosciences is a clinical-stage biopharmaceutical company developing gene and cell therapies derived from the human anti-aging Klotho gene to treat neurodegenerative and age-related disorders, with the primary indications being amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, and other motor neuron disorders. The therapeutic pipeline is anchored by KLTO-202, a gene therapy delivering the Klotho protein to affected neural tissues, which has received FDA Orphan Drug Designation for ALS, and KLTO-101, a second candidate for which GMP manufacturing is planned in 2026. The company is also developing the Klotho Clock, an AI-powered genomics-based diagnostic that measures biological age through DNA methylation analysis of the Klotho gene and eight other longevity-associated genes, with a prototype expected in 2026, intended primarily to enable patient stratification in clinical trials.

The technology platform combines gene therapy delivery methods, genomics-based diagnostics, and a portfolio of intellectual property including 18 accepted patent claims in Australia covering the human secreted Klotho protein (s-KL) and various cellular delivery systems for motor impairment. The company has no commercialized products, no disclosed revenue, and operates with 1–10 employees from Omaha, Nebraska. In March 2026, Klotho completed a reverse-merger acquisition of Greenland Mines Corp., gaining an 80% interest in the Skaergaard palladium-gold-platinum project in Southeast Greenland, with Greenland Mines shareholders expected to hold approximately 93% of the combined entity. Following the transaction, the company plans to rename itself Greenland Mines and change its NASDAQ ticker in late March 2026, effectively pivoting its corporate identity from a clinical-stage biotech to a mining-led entity while retaining the legacy therapeutic and diagnostic programs.

Name

Klotho Neurosciences

Legal name

Klotho Neurosciences Inc.

Website

https://klothoneuro.com

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Klotho Neurosciences is a clinical-stage biopharmaceutical company developing Klotho gene-based gene and cell therapies for neurodegenerative disorders including ALS, Alzheimer's, and Parkinson's. Following a March 2026 reverse merger, it also holds 80% of the Skaergaard palladium-gold-platinum project in Greenland.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Gene Therapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

Keywords

• Gene therapy development
• Neurodegenerative disease treatment
• Biological age diagnostics
• DNA methylation analysis
• Orphan drug development

Headquarters

HQ city

Omaha

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Marketing channels1 record

Core offering

Klotho Neurosciences is a clinical-stage biopharmaceutical company developing cell and gene therapies derived from the human anti-aging Klotho gene to treat neurodegenerative and age-related disorders including ALS, Alzheimer's, and Parkinson's disease. Its lead candidate KLTO-202 has received FDA Orphan Drug Designation. The company is also developing AI-powered genomics-based diagnostic tests, including the Klotho Clock, to measure biological age using DNA methylation analysis for clinical trial patient stratification.

Product overview

Klotho Neurosciences is a clinical-stage biopharmaceutical company developing gene and cell therapies derived from the human Klotho gene to treat neurodegenerative and age-related disorders including ALS, Alzheimer's, and Parkinson's disease. The therapeutic portfolio includes KLTO-202 (lead candidate with FDA Orphan Drug Designation for ALS) and KLTO-101, both targeting motor neuron diseases. The company has expanded into diagnostics with the AI-powered 'Klotho Clock' and a cell-free DNA methylation test for measuring biological age to improve clinical trial patient stratification. Following the March 2026 acquisition of Greenland Mines Corp., the company now operates under two strategic divisions including the Skaergaard Project, one of the world's largest undeveloped palladium-gold-platinum deposits valued at approximately $68 billion.

Differentiator

Problem solved

Functional benefit

Brands

• KLTO-202: Lead therapeutic candidate targeting ALS and other motor neuron diseases; received Orphan Drug Designation from the FDA.
• KLTO-101
• Klotho Clock
• Skaergaard Project

Products and services

• KLTO-202 Lead gene therapy candidate targeting ALS and other motor neuron diseases. Uses gene therapy to deliver the Klotho protein to affected neural tissues to protect neurons and improve disease outcomes. Has received Orphan Drug Designation from the FDA.
• KLTO-101 Therapeutic candidate for neurodegenerative diseases. The company plans to finalize GMP manufacturing of KLTO-101 in 2026 and subsequently initiate clinical trials.
• Klotho Clock AI-powered genomics-based diagnostic test that measures biological age using DNA methylation analysis of the Klotho gene and eight other longevity-associated genes. Combines methylation level measurement with mRNA analysis to assess gene protein production activity. Prototype expected in 2026.
• Cell-Free DNA Methylation Test Genomics-based diagnostic test that analyzes cell-free DNA to determine methylation levels, used for measuring biological age and improving patient stratification in clinical trials for neurodegenerative diseases.

Quantifiable outcome

• FDA Orphan Drug Designation obtained for KLTO-202 for ALS treatment
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• TruDiagnostic: Commercial epigenetic biological age testing company using DNA methylation analysis. Direct competitor to Klotho Clock diagnostic for biological age measurement in research and clinical applications.
• Voyager Therapeutics: Clinical-stage gene therapy company focused on CNS diseases including Parkinson's and ALS using AAV delivery. Direct competitor to Klotho's CNS gene therapy approach with similar indication focus and delivery modality.
• Denali Therapeutics: Biotech developing therapeutics for neurodegeneration including Parkinson's and ALS. Comparable to Klotho in target indication focus, though Denali has a broader small molecule and biologic pipeline and significantly greater resources.
• uniQure: Clinical-stage gene therapy company using AAV delivery for CNS and other indications including ALS. Direct peer in gene therapy modality and CNS disease focus.
• Passage Bio: Clinical-stage gene therapy company focused on CNS disorders including neurodegenerative diseases. Similar stage and modality to Klotho with comparable gene therapy delivery approach.
• MeiraGTx: Clinical-stage gene therapy company developing treatments for CNS and other diseases. Comparable in modality (gene therapy), stage (early clinical), and target disease areas.

Broad incumbents

• Biogen: Large biopharmaceutical company with a focused neurodegenerative disease franchise (ALS, Alzheimer's, Parkinson's). Represents the strategic acquirer profile for Klotho's pipeline and a broad competitive incumbent in target indications.

Emerging players

• Elysium Health (Index): Direct-to-consumer biological age testing service using methylation markers. Comparable to Klotho Clock diagnostic in biological age measurement, though focused on consumer market rather than clinical trial use.
• Axo Neuroscience (formerly Axovant): Clinical-stage company developing gene therapies for neurodegenerative diseases including Parkinson's. Similar modality (gene therapy) and indication overlap with Klotho's CNS pipeline.
• Coya Therapeutics: Clinical-stage biotech developing therapies for ALS and neurodegenerative diseases, including cell therapy approaches. Comparable to Klotho in target indications and clinical-stage cell/gene therapy focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/KlothoNeuroSci
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/klothoneurosciences

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Klotho Neurosciences